Wyeth Laboratories has hired GCI Healthcare to promote a new
treatment for rheumatoid arthritis called Enbrel. Fees are expected to
top pounds 100,000 for the trade account which was won following a
four-way pitch two weeks ago. Rheumatoid arthritis is a severe
inflammatory condition which affects up to 1.5 per cent of the UK
population. The agency will target health professionals through seminars
and specialist media.